Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline.

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%. June 23, 2025 ...

Novo Nordisk became only the eighth company to be suspended from the ABPI in its 40-year history for several transgressions, the most serious of which was a breach of Clause 2 of the code, ...

Read about Novo Nordisk AS ADR (NVO:XNYS) stock and today's latest news and financial updates. NVO - Novo Nordisk AS ADR News | Morningstar Morningstar brands and products ...

Find out if Novo Nordisk AS ADR (NVO:XNYS) stock is overpriced or undervalued based on Morningstar's evaluation. Assess the current comparison of market prices to the Fair Value of the company's ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.